Page 55 - AN-2-1

Advanced Neurology Piribedil for Parkinson’s disease

management. Nat Rev Neurol, 8: 35–47. and pathological gambling in six Parkinsonian patients. Arq
Neuropsiquiatr, 73: 115–118.
https://doi.org/10.1038/nrneurol.2011.189
https://doi.org/10.1590/0004-282X20140212
53. Smith LA, Jackson MJ, Johnston L, et al., 2006, Switching
from levodopa to the long-acting dopamine D2/D3 agonist 63. Perez-Lloret S, Bondon-Guitton E, Rascol O, et al., 2010,
piribedil reduces the expression of dyskinesia while Adverse drug reactions to dopamine agonists: A comparative
maintaining effective motor activity in MPTP-treated study in the French Pharmacovigilance Database. Mov
primates. Clin Neuropharmacol, 29: 112–125. Disord, 25: 1876–1880.
https://doi.org/10.1097/01.WNF.0000220818.71231.DF https://doi.org/10.1002/mds.23204
54. Uppuluri CT, Ravi PR, Dalvi AV, 2021, Design, optimization 64. Stamey W, Jankovic J, 2008, Impulse control disorders and
and pharmacokinetic evaluation of Piribedil loaded solid pathological gambling in patients with Parkinson disease.
lipid nanoparticles dispersed in nasal in situ gelling system Neurologist, 14: 89–99.
for effective management of Parkinson’s disease. Int J Pharm, https://doi.org/10.1097/NRL.0b013e31816606a7
606: 120881.
65. Giugni JC, Tschopp L, Escalante V, et al., 2012, Dose-
https://doi.org/10.1016/j.ijpharm.2021.120881
dependent impulse control disorders in piribedil overdose.
55. TRIVASTAL® 50 mg L.P, Prolonged-Release Coated Tablet. Clin Neuropharmacol, 35: 49–50.
Available from: https://www.servier.ci/sites/default/files/ https://doi.org/10.1097/WNF.0b013e31823d78ab
spc-pil/spc_trivastal_50mg.pdf
66. Tschopp L, Salazar Z, Botello MT, et al., 2010, Impulse
56. Yüksel K, Tuğlular I, 2019, Critical review of European control disorder and piribedil: Report of 5 cases. Clin
medicines agency (EMA) assessment report and related Neuropharmacol, 33: 11–13.
literature on domperidone. Int J Clin Pharm, 41: 387–390.
https://doi.org/10.1097/WNF.0b013e3181c4ae2e
https://doi.org/10.1007/s11096-019-00803-9
67. Perez-Lloret S, Rey MV, Fabre N, et al., 2012, Prevalence and
57. Homann CN, Wenzel K, Suppan K, et al., 2002, Sleep pharmacological factors associated with impulse-control
attacks in patients taking dopamine agonists: Review. BMJ, disorder symptoms in patients with Parkinson disease. Clin
324: 1483–1487.
Neuropharmacol, 35: 261–265.
https://doi.org/10.1136/bmj.324.7352.1483
https://doi.org/10.1097/WNF.0b013e31826e6e6d
58. Perez-Lloret S, Rascol O, 2010, Dopamine receptor agonists 68. Samuel M, Rodriguez-Oroz M, Antonini A, et al., 2015,
for the treatment of early or advanced Parkinson’s disease. Management of impulse control disorders in Parkinson’s
CNS Drugs, 24: 941–968.
disease: Controversies and future approaches. Mov Disord,
https://doi.org/10.2165/11537810-000000000-00000 30: 150–159.
59. Zhang P, Li Y, Nie K, et al., 2018, Hypotension and https://doi.org/10.1002/mds.26099
bradycardia, a serious adverse effect of piribedil, a case 69. Weintraub D, 2008, Dopamine and impulse control
report and literature review. BMC Neurol, 18: 221.
disorders in Parkinson’s disease. Ann Neurol, 64: S93–S100.
https://doi.org/10.1186/s12883-018-1230-1
https://doi.org/10.1002/ana.21454
60. Seppi K, Ray Chaudhuri K, Coelho M, et al., 2019, Update 70. Patel RS, Bhela J, Tahir M, et al., 2019, Pimavanserin in
on treatments for nonmotor symptoms of Parkinson’s Parkinson’s Disease-induced Psychosis: A Literature Review.
disease-an evidence-based medicine review. Mov Disord, Cureus, 11: e5257.
34: 180–198.
https://doi.org/10.7759/cureus.5257
https://doi.org/10.1002/mds.27602
71. Xiao-Ying G, Li Z, Ji-Heng W, et al., 2016, The efficacy
61. Lahrmann H, Cortelli P, Hilz M, et al., 2006, EFNS of levodopa and benserazide combined piribedil in the
guidelines on the diagnosis and management of orthostatic treatment of Parkinson’s disease. Clin Res Pract, 1: 86–87.
hypotension. Eur J Neurol, 13: 930–936.
72. Yan-Bo C, Jin-Jun Q, Cheng-Jie M, et al., 2007, Influence
https://doi.org/10.1111/j.1468-1331.2006.01512.x
of Piribedil on non-motor symptoms in early Parkinson’s
62. Micheli FE, Giugni JC, Espinosa ME, et al., 2015, Piribedil Disease. Chinese J Clin Neurosci, 15: 119–122.

Volume 2 Issue 1 (2023) 13 https://doi.org/10.36922/an.290